Search Results

Redwood Scientific Technologies Inc. (OTC: RSCI) (“Redwood” or “the Company”), a pharmaceutical company, today announced a strategic shift in its product development priorities.

Redwood Scientific Technologies is delighted to announce the successful filing of its S1 registration statement with the Securities and Exchange Commission (SEC).

Eyenovia, Inc. announced that the company’s facility in Redwood City, California successfully completed FDA inspection for approval as a commercial manufacturing facility.

Redwood Scientific Technologies Inc. (RSCI. OTC. PK) announces a partnership with Silk Road Ent., Inc. (SKRJ, OTC, PK) for retail distribution of TBX FREE and TBX VAPE FREE, its smoking cessation products.

Pixelgen Technologies announced today the appointment of Mostafa Ronaghi , Ph.D., to its Scientific Advisory Board.

Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology self-care product being developed for the treatment of dry eye.

Cytokinetics, Incorporated announced that positive results from Cohort 4 of REDWOOD-HCM, a Phase 2 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy, were presented at the American College of Cardiology 72nd Annual Scientific Session.

ANEW MEDICAL, INC., an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp., a publicly traded special purpose acquisition company, or SPAC.

Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material.